Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas and advocated defensive surgical and adjuvant treatment. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).